Abstracts tagged "Antibodies"

Abstract Number: 647 • 2016 ACR/ARHP Annual Meeting
Genomic and Epigenetic Bioinformatics Demonstrate Dual TNF-α and IL17A Target Engagement By ABT-122, and Suggest Mainly TNF-α–Mediated Relative Target Contribution to Drug Response in MTX-IR Rheumatoid Arthritis Patients
Robert W. Georgantas III¹, Melanie Ruzek², Justin Wade Davis¹, Feng Hong¹, Elizabeth Asque¹, Kenneth Idler¹, Heikki T. Mansikka¹, Benoit Guerette¹ and Jeffrey F. Waring¹, ¹AbbVie Inc., North Chicago, IL, ²Immunology Discovery, AbbVie, Worcester, MA
Background/Purpose: ABT-122 is a dual variable domain (DVD-Ig) biologic which inhibits TNF-α and IL17A. In a 12-wk phase 2 study (NCT02141997) in MTX-IR patients (pts)…
Abstract Number: 2841 • 2016 ACR/ARHP Annual Meeting
Anti-Ro52/TRIM21 Antibodies Are Associated with QT Interval Prolongation in Patients with Systemic Lupus Erythematosus
Luis F. Perez-Garcia¹, Irving Omar Estevez-Garcia¹, Mariana Moreno Ramirez¹, Javier Loaiza Felix¹, Ricardo Marquez-Velasco², Pedro Iturralde³, Luis H. Silveira^4,5 and Luis M. Amezcua-Guerra¹, ¹Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ²Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ³Cardiology - Electrophysiology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁴Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, ⁵Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico
Background/Purpose: Long QT syndrome (LQTS) is characterized by an abnormal QT corrected (QTc) interval prolongation that is associated with increased risk of sudden death. Studies…
Abstract Number: 650 • 2016 ACR/ARHP Annual Meeting
ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain (DVD)–Ig™ in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial
Mark C. Genovese¹, Michael Weinblatt², Jacob A Aelion³, Heikki T. Mansikka⁴, Paul M. Peloso⁴, Kun Chen⁴, Yihan Li⁴, Ahmed A. Othman⁴, Amit Khatri⁴, Nasser S. Khan⁴ and Robert J. Padley⁴, ¹Stanford University Medical Center, Palo Alto, CA, ²Brigham and Women’s Hospital, Boston, MA, ³West Tennessee Research Institute, Jackson, TN, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Tumor necrosis factor (TNF) and interleukin 17 (IL-17) appear to independently contribute to the pathophysiology of rheumatoid arthritis (RA), synergistically inducing inflammatory mediators leading…
Abstract Number: 2875 • 2016 ACR/ARHP Annual Meeting
Depressed Serum IgM Levels in SLE Are Restricted to Defined Subgroups
Caroline Grönwall¹, Uta Hardt¹, Iva Gunnarsson², Gregg J. Silverman³ and Elisabet Svenungsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Department of Medicine, Unit of Rheumatology, Stockholm, Sweden, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Natural IgM autoantibodies have been proposed to have protective properties, and decreased levels of IgM to phosphorylcholine (PC) in SLE are associated with higher…
Abstract Number: 726 • 2016 ACR/ARHP Annual Meeting
Comparison of Infliximab Immunogenicity in Inflammatory Arthritis Versus Inflammatory Bowel Disease Patients in Routine Clinical Practice
Marianne Guirgis¹, Melanie Favre dit Jeanfavre², Charles Benaim³, Matthieu Perreau⁴, Pierre Michetti⁵, Michel Maillard¹ and Pascal Zufferey⁶, ¹gastroenterology, Lausanne, Switzerland, ²DAL, RHU, Lausanne, Switzerland, ³DAL, MPR, Lausanne, Switzerland, ⁴Medecine /CHUV, Immunology, Lausanne, Switzerland, ⁵La Source-Beaulieu, Lausanne, Switzerland, ⁶Rhu /Dal .Chuv, Rheumatology, Lausanne, Switzerland
Background/Purpose: Infliximab is a biological agent frequently used for inflammatory arthritis (IA) such as spondyloarthritis, rheumatoid arthritis, psoriatic arthritis as well as for the inflammatory…
Abstract Number: 2905 • 2016 ACR/ARHP Annual Meeting
Predictors of Poor Hand Function in Systemic Sclerosis
Ashraf Raslan¹ and Vivien Hsu², ¹Medicine, Rutgers-RWJ Medical School, Jersey City, NJ, ²Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ
Background/Purpose: Systemic Sclerosis (SSc) is a progressive systemic disease that can lead to variable degrees of morbidity and disability. Hand dysfunction in SSc patients [1]…
Abstract Number: 830 • 2016 ACR/ARHP Annual Meeting
Cardiopulmonary Disease Development in Anti-RNA Polymerase III Positive Systemic Sclerosis; Comparative Analyses from an Unselected, Prospective Patient Cohort
Anna Hoffmann-Vold¹, Anders Heiervang Tennøe², Oyvind Midtvedt², May Brit Lund³, Torhild Garen², Fadi El-Hage⁴, Trond Mogens Aalokken⁵, Eli Taraldsrud⁴ and Øyvind Molberg², ¹Division of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Rheumatology, Oslo University Hospital, Oslo, Norway, ³Respiratory Medicine, Oslo University Hospital, Oslo, Norway, ⁴Oslo University Hospital, Oslo, Norway, ⁵Radiology, Oslo University Hospital, Oslo, Norway
Background/Purpose: Extensive skin disease and renal crisis are hallmarks of anti-RNA polymerase III (RNAP) positive systemic sclerosis (SSc), while data on lung and heart involvement…
Abstract Number: 3225 • 2016 ACR/ARHP Annual Meeting
Dual Cytokine Inhibition with ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain Immunoglobulin (DVD-Ig™): Results from a 24-Week Open-Label Extension Study in Patients with Rheumatoid Arthritis
Mark C. Genovese¹, Michael Weinblatt², Heikki T. Mansikka³, Paul M. Peloso³, Kun Chen³, Yihan Li³, John Liu³ and Robert J. Padley³, ¹Stanford University Medical Center, Palo Alto, CA, ²Brigham and Women’s Hospital, Boston, MA, ³AbbVie Inc., North Chicago, IL
Background/Purpose: ABT-122 is a dual variable domain immunoglobulin (DVD-Ig™) that targets human tumor necrosis factor-α (TNF-α) and interleukin-17A (IL-17A). The object was to investigate the…
Abstract Number: 1011 • 2016 ACR/ARHP Annual Meeting
Correlations Between B Cell Epitope Specificity and Clinical Features in Patients with Jo-1 Antibodies and the Anti-Synthetase Syndrome
Joseph LaConti¹, Fanny Kippelen², Rohit Aggarwal³ and Dana P. Ascherman⁴, ¹Division of Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ²Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, ³Department of Medicine / Rheumtology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL
Correlations Between B Cell Epitope Specificity and Clinical Features in Patients with Jo-1 Antibodies and the Anti-Synthetase Syndrome Background/Purpose: Idiopathic inflammatory myopathy (IIM) is an…
Abstract Number: 3243 • 2016 ACR/ARHP Annual Meeting
Intestinal Microbial Dysbiosis in SLE Is Linked to Elevated IgA and Induction of Autoimmunity
Doua F. Azzouz¹, Lelise Getu², Celine Anquetil¹, Jill P. Buyon³ and Gregg J. Silverman³, ¹Medicine, NYU School of Medicine, New York, NY, ²Department of Medicine, New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY
Background/Purpose: SLE is a complex multifactorial systemic autoimmune disease, which has been attributed to poorly understood interactions between genetic and environmental factors. Recent reports have…
Abstract Number: 1347 • 2016 ACR/ARHP Annual Meeting
Steroid-Responsive Encephalopathy Associated with Autoimmune Thyroiditis: Characteristics, Treatment and Outcome in 251 Cases from the Literature
Charlotte Laurent¹, Jean Capron², Sonia Alamowitch³, Bluenn Quillerou⁴, Guy Thomas⁴, Olivier Fain⁵ and Arsène Mékinian⁵, ¹Internal Medicine, Internal Medicine, Hôpital Saint-Antoine, Paris, paris, France, ²Neurology, Neurology, Hôpital Saint-Antoine, paris, France, ³Neurology, Neurology - Hopital St Antoine, paris, France, ⁴Psychiatry, Psychiatry Hopital St Antoine, paris, France, ⁵Service de médecine interne. Hôpital Saint-Antoine., Paris, France
Background/Purpose: Steroid-responsive encephalopathy and associated autoimmune thyroiditis (SREAT) is characterized by encephalopathy and the presence of antithyroid antibodies. We describe the clinical presentation, outcome and…
Abstract Number: 1353 • 2016 ACR/ARHP Annual Meeting
Risk Factors of Pulmonary Mycobacterium Avium-Comlex (MAC) Disease and the Significance of Anti-MAC Antibody in Patients with Rheumatic Diseases
Tamao Nakashita¹, Shinji Motojima², Akira Jibatake², Akira Yoshida² and Yoshiki Yamamoto², ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan
Background/Purpose: Pulmonary MAC disease is caused by MAC and the incidence is increasing in Japan. It is also becoming a great concern in the field…
Abstract Number: 1369 • 2016 ACR/ARHP Annual Meeting
Features Distinguishing Clinically Hypo- and Amyopathic Juvenile Dermatomyositis (CAJDM) from Juvenile Dermatomyositis (JDM)
Gulnara Mamyrova¹, Takayuki Kishi², Nastaran Bayat², Ira N. Targoff³, Lan Wu², Olcay Y. Jones^1,4, Rodolfo Curiel¹, Frederick W. Miller² and Lisa G. Rider^1,2, ¹Rheumatology, George Washington University, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, ³University of Oklahoma, Oklahoma City, OK, ⁴Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: Clinically Amyopathic Juvenile Dermatomyositis (CAJDM) is a distinct clinical phenotype of JDM in which patients (pts) often have characteristic JDM rashes with little…
Abstract Number: 483 • 2015 ACR/ARHP Annual Meeting
Antibody to Malondialdehyde-Acetaldehyde (MAA) Adducts Serve As Biomarkers of Treatment Response in Rheumatoid Arthritis
Ted R. Mikuls¹, Brian Coburn¹, Harlan Sayles², Fang Yu³, Mary Brophy⁴, James R. O'Dell¹, Lynell W. Klassen⁵ and Geoffrey M. Thiele¹, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Public Health, University of Nebraska Medical Center, Omaha, NE, ⁴VA Boston Heathcare System, Boston, MA, ⁵Dept of Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Previous reports have demonstrated that malondialdehyde-acetaldehyde (MAA) adducts are produced as a byproduct of oxidative stress and lipid peroxidation and are expressed in…
Abstract Number: 2376 • 2015 ACR/ARHP Annual Meeting
Clinical Features in Dermatomyositis Patients with Novel Autoantibody to Small Ubiquitin-like Modifier Activating Enzymes (Anti-SAE Antibody) and Relationship to Interstitial Lung Disease: A Systematic Review of 29 Cases
Sirada Panupattanapong¹, Jessica Sun² and Kevin Baszis¹, ¹Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ²Pediatric, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO
Background/Purpose: Anti-SAE antibody is a novel myositis-specific antibody first described in 2007. SAE is an enzyme that facilitates sumoylation, leading to the formation of stable…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].